Concept:Tumor marker binding specificity of targeted monoclonal antibodies.
Solution:Malignant cells frequently overexpress unique surface antigens known as tumor markers (e.g., PSA, CEA, HER2). Monoclonal antibodies specifically target and bind to these antigens in biopsy tissue or serum samples, facilitating accurate early detection.
Why other options are incorrect:- Replacing damaged tissue: Tissue regeneration is mediated by stem cell therapy and tissue engineering scaffold matrices, not antibodies.
- Changing the genetic code of cancer cells: Gene editing technologies (such as CRISPR-Cas9) alter genetic sequences, not monoclonal antibodies.
- Killing healthy cells to reduce tumor spread: Diagnostic procedures aim to preserve healthy host tissues without unnecessary cytotoxicity.
Quality & Fidelity Assurance:
Every question on BeambePrep is rigorously curated against the official PMDC syllabus with zero filler, zero out-of-syllabus content, and zero typos. When an authentic past paper originally contained a historical mistake or ambiguity from the examining board (such as UHS or NUMS), BeambePrep faithfully reflects the original paper while detailing the nuance and scientific consensus in the autopsy above.